Advertisement

Picture Berlin Partner German Biotech Days 2024 in Berlin 650x100px
Document › Details

BioNTech SE. (12/28/22). "Press Release: BioNTech to Present at the 41st Annual J.P. Morgan Healthcare Conference". Mainz.

Region Region San Francisco, CA
  Country United States (USA)
Organisations Organisation BioNTech SE (Nasdaq: BNTX)
  Group BioNTech (Group)
  Organisation 2 J.P. Morgan Securities LLC
  Group JPMorgan Chase (Group)
Products Product J.P. Morgan 41st Annual Healthcare Conference 2023 San Francisco
  Product 2 mRNA-based vaccine
Index term Index term BioNTech–JPMorgan Chase: investor conference, 202301 supply service BioNTech presents at JP Morgan Healthcare Conference 2023
Persons Person Sahin, Ugur (BioNTech 201207 Managing Director BioNTech + Ribological GmbH)
  Person 2 Maas, Sylke (BioNTech 202005 VP Investor Relations + Business Strategy)
     


BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) announced today that CEO and Co-founder Prof. Ugur Sahin, M.D., will present a corporate overview and update at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023, at 9:45 am PST / 12:45 pm ET.

A live webcast of the presentation will be available via the “Events & Presentations” page in the Investor Relations section on the Company’s website at https://biontech.com/. The replay of the webcast will be archived on the Company’s website for 30 days following the conference.


About BioNTech

Biopharmaceutical New Technologies is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. The Company exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bispecific immune checkpoint modulators, targeted cancer antibodies and small molecules. Based on its deep expertise in mRNA vaccine development and in-house manufacturing capabilities, BioNTech and its collaborators are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline. BioNTech has established a broad set of relationships with multiple global pharmaceutical collaborators, including Genmab, Sanofi, Genentech, a member of the Roche Group, Regeneron, Genevant, Fosun Pharma, and Pfizer.

For more information, please visit www.BioNTech.com.


CONTACT

Investor Relations
Sylke Maas, Ph.D.
+49 (0)6131 9084 1074
Investors@biontech.de

Media Relations
Jasmina Alatovic
+49 (0)6131 9084 1513
Media@biontech.de

   
Record changed: 2024-01-06

Advertisement

Picture Swiss Biotech Association Swiss Biotech Days 2024 SBD24 Basel 650x200px

More documents for BioNTech (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture Berlin Partner German Biotech Days 2024 in Berlin 650x300px




» top